Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: Improvement with treatment and worsening following discontinuation

European Neuropsychopharmacology

Volumn 24, Issue 3, 2014, Pages 375-380

  Pallanti, Stefano ^a,b,c   Bernardi, Silvia ^a,b   Antonini, Sarah ^b   Singh, Nikhilesh ^d   Hollander, Eric ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF FLORENCE   (Italy)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d Transcept Pharmaceuticals Inc   (United States)

Author keywords

5 HT3; Augmentation; Low dose ondansetron; OCD

Indexed keywords

ANXIOLYTIC AGENT; ONDANSETRON; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; CAUCASIAN; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; DRUG POTENTIATION; FEMALE; HUMAN; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PSYCHOLOGICAL RATING SCALE; SINGLE BLIND PROCEDURE; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTI-ANXIETY AGENTS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; ONDANSETRON; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84894335765     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2013.12.003     Document Type: Article

References (27)

1. Bloch M.H., Landeros-Weisenberger A., Kelmendi B., Coric V., Bracken M.B., Leckman J.F. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol. Psychiatry 2006, 11(7):622-632.
2. Bloom F.E., Morales M. The central 5-HT3 receptor in CNS disorders. Neurochem. Res. 1998, 23(5):653-659.
3. Brady R.E., Adams T.G., Lohr J.M. Disgust in contamination-based obsessive-compulsive disorder: a review and model. Expert Rev. Neurother. 2010, 10(8):1295-1305.
4. Broocks A., Pigott T.A., Hill J.L., Canter S., Grady T.A., L'Heureux F., et al. Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results. Psychiatry Res. 1998, 79(1):11-20.
5. Charney D.S., Goodman W.K., Price L.H., Woods S.W., Rasmussen S.A., Heninger G.R. Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. Arch. Gen. Psychiatry 1988, 45(2):177-185.
6. Diagnostic and Statistical Manual of Mental Disorders, 2000. 4th TR ed. Washington, DC.
7. Eisen J.L., Mancebo M.A., Pinto A., Coles M.E., Pagano M.E., Stout R., et al. Impact of obsessive-compulsive disorder on quality of life. Compr. Psychiatry 2006, 47(4):270-275.
8. First, M., Spitzer, R., Gibbon, M., 1996. Structured Clinical Interview for DSM-IV Axis I Disorder. Clinical Version (SCID-CV). Washington DC.
9. Goodman W.K., McDougle C.J., Price L.H., Barr L.C., Hills O.F., Caplik J.F., et al. m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: absence of symptom exacerbation. Biol. Psychiatry 1995, 38(3):138-149.
10. Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Fleischmann R.L., Hill C.L., et al. The Yale-Brown obsessive compulsive scale. I. Development, use, and reliability. Arch. Gen. Psychiatry 1989, 46(11):1006-1011.
11. Guy, W., 1976. ECDEU Assessment Manual for Psychopharmacology. National Institute of Mental Health, Rockville, MD.
12. Hasler S.B., Hirt A., Ridolfi L.A., Leibundgut K.K., Ammann R.A. Safety of ondansetron loading doses in children with cancer. Support Care Cancer 2008, 16(5):469-475.
13. Hewlett W.A., Schmid S.P., Salomon R.M. Pilot trial of ondansetron in the treatment of 8 patients with obsessive-compulsive disorder. J. Clin. Psychiatry 2003, 64(9):1025-1030.
14. Hollander E., Pallanti S. Current and experimental therapeutics of OCD. Neuropsychopharmacology: The Fifth Generation of Progress 2002, 1647-1664. Lippincott Williams & Wilkins, Philadelphia. K.L. Davis, D. Charney, J.T. Coyle, C. Nemeroff (Eds.).
15. Joharchi N., Sellers E.M., Higgins G.A. Effect of 5-HT3 receptor antagonists on the discriminative stimulus properties of morphine in rats. Psychopharmacology (Berl) 1993, 112(1):111-115.
16. Koob G.F. Neural mechanisms of drug reinforcement. Ann. N. Y. Acad. Sci. 1992, 654:171-191.
17. Koran L.M., Hanna G.L., Hollander E., Nestadt G., Simpson H.B. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am. J. Psychiatry 2007, 164(7 Suppl.):5-53.
18. Lamers C.B.H.W. Ondansetron: effects on gastrointestinal motility. Scand. J. Gastroenterol. 1991, 26(Suppl. 188):124-126.
19. March J., Frances A., Carpenter D., Kahn D. The expert consensus guideline series. J. Clin. Psychiatry 1997, 58(Suppl. 4):1-64.
20. Miyata K., Ito H., Yamano M., Hidaka K., Kamato T., Nishida A., Yuki H. Comparison of the effects of trimebutine and YM114 (KAE-393), a novel 5-HT3 receptor antagonist, on stress-induced defecation. Eur. J. Pharmacol. 1993, 250(2):303-310.
21. Pallanti S., Bernardi S., Antonini S., Singh N., Hollander E. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study. CNS Drugs 2009, 23(12):1047-1055.
22. Rapaport M.H., Clary C., Fayyad R., Endicott J. Quality-of-life impairment in depressive and anxiety disorders. Am. J. Psychiatry 2005, 162(6):1171-1178.
23. Soltani F., Sayyah M., Feizy F., Malayeri A., Siahpoosh A., Motlagh I. A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder. Hum. Psychopharmacol. 2010, 25(6):509-513.
24. Stengler-Wenzke K., Kroll M., Matschinger H., Angermeyer M.C. Quality of life of relatives of patients with obsessive-compulsive disorder. Compr. Psychiatry 2006, 47(6):523-527.
25. Tonini M. 5-Hydroxytryptamine effects in the gut: the 3, 4, and 7 receptors. Neurogastroenterol. Motil. 2005, 17(5):637-642.
26. Urraca N., Camarena B., Gomez-Caudillo L., Esmer M.C., Nicolini H. Mu opioid receptor gene as a candidate for the study of obsessive compulsive disorder with and without tics. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2004, 127B(1):94-96.
27. Ye J., Ponnudurai R., Schaefer R. Ondansetron: a selective 5-HT3 receptor antagonist and its applications in CNS-related disorders. CNS Drug Rev. 2001, 7(2):199-213.